On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a ...

Spotify Technology on Tuesday beat analyst estimates for subscribers and users in the fourth quarter. Spotify stock jumped.

Cramer noted that the Dow plunged by 337 points, the S&P 500 fell 0.5%, and the Nasdaq declined by 0.28%. Adding fuel to the ...

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

Jim Cramer, host of Mad Money, recently discussed some of the significant challenges the alcohol industry is facing. He pointed out that as the end of January approaches, the wine and spirits industry ...

Amrita Sen, director of research at Energy Aspects, discusses the potential impact of President Donald Trump's 10% tariff on ...

After a market-wide panic over AI start-up DeepSeek, CNBC’s Jim Cramer reflected on what the new player’s entrance into the ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where FMC Corporation (NYSE:FMC) stands against the other stocks on Jim Cramer's ...

Jim Cramer, host of Mad Money ... Beyond GLP-1 drugs, healthcare companies are expanding their portfolios with new cancer therapies, treatments for eye care and asthma, and experimental drugs ...

CNBC's Jim Cramer examined Wednesday's market action and stressed that it's often important to stay focused on corporate earnings and commentary from management. "The people who chatter endlessly ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...